ILLUSTRATED REVIEW

An illustrated review of bleeding assessment tools and common coagulation tests

Carolyne Elbaz MDCM, FRCPC1 | Michelle Sholzberg MDCM, MSc, FRCPC2,3

1Department of Medicine, University of Toronto, Toronto, ON, Canada
2Departments of Medicine and Laboratory Medicine & Pathobiology, St. Michael’s Hospital, Toronto and University of Toronto, Toronto, ON, Canada
3Li Ka Shing Knowledge Institute, Toronto, ON, Canada

Correspondence
Carolyne Elbaz, Department of Medicine, University of Toronto, 1007 - 30 Roehampton, Toronto, ON M4P 0B9, Canada.
Email: carolyne.elbaz@mail.mcgill.ca

Abstract
Recognizing the complexity of coagulation tests and currently used anticoagulants, we developed this illustrated review on bleeding assessment tools and common coagulation screening tests. Quantitative bleeding assessment tools (BATs) are available to standardize the bleeding history and improve the pretest probability prior to coagulation testing. We describe use of BATs and the principles, indications, and limitations of the prothrombin time (PT)/International Normalized Ratio, activated partial thromboplastin time (APTT), and 50:50 mix. Use of these tests to identify coagulation factor deficiencies, specific and nonspecific inhibitors, coagulopathy of liver disease, disseminated intravascular coagulation, and commonly used anticoagulant medications are reviewed. Current literature suggests that unnecessary coagulation testing is rampant. The PT and APTT have astoundingly low sensitivity (1.0%-2.1%) for detection of clinically significant bleeding disorders. Thus, current guidelines recommend against the use of screening PT and APTT in preoperative patients undergoing noncardiac/vascular surgery.

KEYWORDS
bleeding disorders, clinical laboratory techniques, hemorrhage, International Normalized Ratio, thrombosis

Essentials
- Quantitative bleeding assessment tools standardize the bleeding history and improve the pretest probability of bleeding disorders prior to coagulation testing.
- Unnecessary coagulation testing is rampant.
- Thorough understanding of common hemostatic tests is essential for appropriate selection and interpretation of tests.
The patient history is the most important tool in determining the pre-test probability of a bleeding disorder. Quantitative bleeding assessment tools (BATs) have thus been developed to standardize the bleeding history and guide appropriate testing to investigate bleeding disorders. Bleeding scores are based on symptom frequency and severity (i.e., need for surgical or medical attention).

| Year | BAT Name                          | Normal Score Basis                              | Description                                      |
|------|----------------------------------|-------------------------------------------------|--------------------------------------------------|
| 2005 | Vicenza BAT                      | ISTH provisional criteria for Type 1 VWD       | This BAT prioritizes bleeding symptoms that lead to medical attention and treatment of bleeding symptoms. |
| 2010 | ISTH BAT                         | provisional criteria for Type 1 VWD             | In 2010, the International Society of Thrombosis and Haemostasis (ISTH) BAT was developed. |

**Bleeding Assessment Tools (BAT)**

**A bit about BATs...**

The Vicenza BAT was validated in 2005 based on the ISTH provisional criteria for the diagnosis of Type 1 von Willebrand Disease (VWD).[13]

This BAT prioritizes bleeding symptoms that lead to medical attention and treatment of bleeding symptoms.

In 2010, the International Society of Thrombosis and Haemostasis (ISTH) BAT was developed.[7,14]

BATs require expert administration (e.g., nurse or physician).

Therefore, the ISTH-BAT was converted to a patient self-administered BAT (Self-BAT).[6]

The European Molecular and Clinical Markers for the Diagnosis and Management of Type 1 VWD (MCMDM-1 VWD BAT)[2,17] was developed initially in 2006, and shortened in 2008 to allow for a short administration time.

The Pediatric Bleeding Questionnaire (PBQ)[3] was then developed, adding pediatric-specific bleeding symptoms to the MCMDM1-VWD.

The Pediatric Bleeding Questionnaire (PBQ)[3] was then developed, adding pediatric-specific bleeding symptoms to the MCMDM1-VWD.

| BAT                | Sensitivity | Specificity |
|--------------------|-------------|-------------|
| Vicenza BAT        | 69%         | 98%         |
| Condensed MCMDM-1 VWD | 100%    | 87%         |
| PBQ                | 83%         | 79%         |
| ISTH BAT           | 64%         | 99%         |
| Self BAT           | 78%         | 23%         |

Bleeding score is higher with increasing VWD severity[2]
There are many validated BATs. The following are some key distinctive features:
- The MCMDM-1 VWD and PBQ assign negative points for hemostatic challenges without bleeding complications (i.e. surgeries, deliveries, dental extractions).
- The ISTH BAT and PBQ evaluate pediatric bleeding symptoms in the “other bleeding” category (i.e. cephalohematoma, umbilical stump bleeding, cheek hematoma and conjunctival hemorrhage).
- The ISTH BAT assesses menorrhagia more comprehensively and is the only BAT that evaluates hematuria.

### Bleeding symptom categories in the ISTH BAT

#### Spontaneous bleeding
- Intracranial bleeding
- Bruising
- Bleeding from minor wounds
- Muscle hematomas
- Hemarthrosis

#### Epistaxis
- Oral cavity bleeding
- Gastrointestinal bleeding
- Menorrhagia
- Hematuria

#### Bleeding after hemostatic challenges:
- Tooth extraction
- Post partum hemorrhage
- Surgery

### Did you know?

In a study using the Condensed MCMDM-1, ISTH BAT and PBQ to evaluate bleeding symptoms in 927 patients with excessive bleeding, the investigators found that history of hemarthrosis, post surgical bleeding and menorrhagia increased the likelihood of laboratory confirmed VWD. In addition, the number of bleeding symptoms increased the odds ratio for a VWD diagnosis.[16]
Coagulation cascade with sites of action of commonly used anticoagulants

Vitamin K antagonists prevent the γ-carboxylation of FII, FVII, FIX, FX.

Early contact pathway factors
- FXIIa
- FXIa
- FXa

Fx inhibitors
- Direct
  - Rivaroxaban
  - Apixaban
  - Edoxaban
- Indirect
  - Fondaparinux

Unfractionated heparin potentiates antithrombin (AT) to inactivate FIIa, FXa, FIXa, FXIa, FXIIa.

Extrinsic tenase FVIIa-TF

Intrinsic tenase FVIIIa-FIXa

Prothrombinase complex FVa-FXa

Prothrombin

Thrombin

Fibrinogen

Fibrin clot

Direct Thrombin Inhibitors
- Dabigatran
- Argatroban

LMWH potentiates antithrombin (AT) to inactivate FIIa and FXa
**Prothrombin time (PT)**

**Quick’s Time**

1. **Collect sodium citrate tube**
2. **Centrifuge to obtain platelet poor plasma (PPP) and warm at 37°C**
3. **Combine with thromboplastin (contains phospholipids) and calcium chloride**
4. **Once fibrin strands are detected, the timer stops and the PT is reported in seconds.**

**The PT can assess for deficiencies or inhibitors of the extrinsic pathway factors (FVII) and common pathway factors (FX, FV, FII, fibrinogen).**

The relationship between the PT and a factor deficiency is not linear and increases exponentially at lower factor concentrations[18].
Prothrombin time (PT)  
International Normalized Ratio (INR)

If the PT is prolonged but the aPTT is not, consider:

1. Acquired deficiency of FVII
   - Early warfarin therapy
   - Early vitamin K deficiency
   - Early liver disease

2. Drugs: Direct Xa inhibitors (e.g., rivaroxaban, apixaban, edoxaban, but typically prolong the aPTT too)[15]

3. Congenital deficiency of FVII

4. Specific inhibitors to FVII (exceptionally rare)

The INR was developed in the 1980s to standardize the PT which allowed for the monitoring of oral vitamin K antagonist therapy (e.g. warfarin, acenocoumarol) across different labs.[11,12]

Each lot of PT reagent has an International Sensitivity Index (ISI) which indicates the sensitivity of the reagent to deficiencies of the Vitamin K dependent factors compared with the WHO reference standard.

\[
\text{INR} = \left( \frac{\text{Patient PT}}{\text{Geometric mean of normal PT}} \right)^{\text{ISI}}
\]

**Warfarin** is a competitive inhibitor of oxidized vitamin K and interferes with its reduction, making Vitamin K unavailable for the vitamin K dependent carboxylase enzyme to y-carboxylate FII, VII, IX, X.

**Vitamin K reductase**

Oxidized vitamin K → Reduced Vitamin K

Functional factors II, VII, IX, X

**Vitamin-K-dependent carboxylase**

is a vitamin-K-dependent enzyme responsible for the y-carboxylation of factors II, VII, IX, X. Factors are then capable of interacting with other components of coagulation.

**Caution**

The PT/INR can be NORMAL with mild single factor deficiencies due to differential reagent sensitivity.

The relationship between the PT and a factor deficiency is not linear and increases exponentially at lower factor concentrations[18].
Activated Partial Thromboplastin Time (aPTT)

Collect sodium citrate tube

Centrifuge to obtain platelet poor plasma (PPP) and warm at 37°C

Combine contact activator (ellagic acid, silica, kaolin or glass beads), phospholipids and calcium chloride

Once fibrin strands are detected, the timer stops and the aPTT is reported in seconds.

The aPTT can assess for deficiencies or inhibitors of the intrinsic pathway factors (early contact factors, FXII, FXI, FIX, FVIII) and common pathway factors (FX, FV, FII, fibrinogen).

The relationship between the aPTT and a factor deficiency is not linear and prolongs exponentially at lower factor concentrations.[18]
Activated Partial Thromboplastin Time (aPTT)

If the aPTT is prolonged but the PT is not, consider:

1. Therapeutic unfractionated heparin (other anticoagulants may prolong the aPTT alone but typically prolong the PT too)

2. Non specific inhibitors (e.g. antiphospholipid antibodies)[8]

3. Congenital intrinsic coagulation factors deficiencies: contact pathway factors (prekallikrein, kallikrein, HMWK), FXII, FXI, FIX, FVIII)

4. Specific inhibitors to one factor (e.g. FVIII antibody)

---

**Caution**

The aPTT can be normal with mild single factor deficiencies and is often normal in von Willebrand disease

---

**Did you know?**

In a study reviewing 100 samples with a prolonged aPTT, 14% were due to venipuncture artifact [10]
Causes include:

1. **Pre-analytical cause**
   (e.g. heparin contamination, under filling of tube)

2. **Drugs**
   Direct or indirect inhibitory drugs
   (e.g. direct thrombin inhibitors, heparin)
   Supratherapeutic warfarin effect
   (FII, FVII, FIX, FX <30%)

3. **Inhibitors**
   Non specific inhibitor
   (e.g. antiphospholipid antibodies)
   Specific inhibitors to the common pathway factors (rare)

4. **Decreased factor synthesis**
   - Congenital deficiency
   - Reduced liver synthesis
     (impaired production FII, FV, FVII, FIX, FX, FXI, FXII, FXIII, dysfibrinogenemia)
   - Severe vitamin K deficiency (↓FII, FVII, FIX, FX)

5. **Factor consumption or binding**
   - Massive hemorrhage
   - Disseminated intravascular coagulation (DIC)
   - Factor X deficiency associated with systemic amyloidosis

### Changes in hemostasis in DIC and liver disease

| Prohemostatic changes | DIC | Liver disease |
|------------------------|-----|--------------|
| Primary hemostasis     | ↑VWF| ↑VWF         |
|                        | ↓ADAMTS13| ↓ADAMTS13 |
| Secondary hemostasis   | ↑Factor VII | ↓Factor VII |
|                        | ↓Protein C, protein S, antithrombin, heparin cofactor II | ↑Protein C, protein S, antithrombin |
| Fibrinolysis           | ↓Plasminogen | ↑Plasminogen |

| Antihemostatic changes | DIC | Liver disease |
|------------------------|-----|--------------|
| Primary hemostasis     | Thrombocytopenia | Abnormal platelet function |
|                        | ↑α2-antiplasmin, factor XII, TAFI | ↑α2-antiplasmin, factor XII, TAFI |
| Secondary hemostasis   | ↓Factors II, V, VII, X, XII, XII | ↓Factors II, V, VII, X, XII, XII |
|                        | ↓Plasminogen | ↑Plasminogen |
| Fibrinolysis           | ↓t-PA | ↑t-PA |

**Caution**

- **FVIII may be high in early DIC**

---

**ADAMTS13**: A Disintegrin and Metalloproteinase with a Thrombospondin type 1 motif, member 13; **PAI-1**: Plasminogen Activator Inhibitor type 1; **t-PA**: Tissue Plasminogen Activator; **TAFI**: Thrombin Activatable Fibrinolysis Inhibitor; **TFPI**: Tissue Factor Pathway Inhibitor; **VWF**: Von Willebrand Factor.

The ISTH DIC scoring system was developed in 2001 and uses widely available coagulation assays[1]

| Points | 0 | 1 | 2 | 3 |
|--------|---|---|---|---|
| Platelet count (10⁹/L) | > 100 | 50-100 | < 50 |
| Level of fibrin markers (e.g. D-dimer) | No increase | Increased but < 5x upper limit of normal | Strong increase, ≥ 5x upper limit of normal |
| Prolonged prothrombin time (seconds) | < 3 | ≥ 3 and < 6 | ≥ 6 |
| Fibrinogen (g/L) | > 1.0 | ≤ 1.0 |

A score ≥ 5 is has a sensitivity of 93% and specificity of 98% for the diagnosis of DIC.

The severity of this score is a strong predictor for mortality in sepsis.

---

ILLUSTRATED REVIEW

Differential Diagnosis for a Prolonged PT and aPTT

If the PT and the aPTT are both prolonged, there could be multiple factors affected in the intrinsic and extrinsic pathways or a single factor deficiency in the common pathway: FX, FV, FI or severe fibrinogen deficiency.
**Workup of a Prolonged PT or aPTT**

**Investigations**
To distinguish between a single factor deficiency and inhibitor, an immediate 50:50 mix is performed when the prolongation is greater than 4 seconds from the upper limit of normal.

- **Control plasma**
- **Patient plasma**
- **An aPTT or a PT is then performed on the 50:50 mix.**

**Interpretation**
The mixture “corrects” if the aPTT is within 3-4 seconds of normal and the PT is within 2 seconds of normal.

- **Does not correct**
- **Corrects**
- **Specific inhibitor**
- **Non-specific inhibitor**
- **Multiple factor deficiencies**
- **Suggests single factor deficiency**

**Caution**
The 50:50 mix may not completely correct in the case of multiple factor deficiencies.

**Specific factor levels are more informative than the 50:50 mix.**
Specific factor levels are performed by combining one part patient’s sample with commercial factor deficient plasma.

- **Factor deficient plasma: Commercial plasma completely deficient in a factor relevant to the PT (e.g. FVII, X) or aPTT (e.g. FVIII, IX, XI, XII).**
- **An aPTT or PT is performed on the mix and factor levels are derived from a calibration curve.**

**The Bethesda assay is used to quantitate specific factor inhibitors.**
One Bethesda unit is defined as that amount of inhibitor that results in 50% residual FVIII:C activity after incubation at 37°C for two hours. No incubation is needed for factor inhibitors that are not time sensitive (i.e. FIX).

The inhibitor concentration is derived from a graph depicting factor VIII (Y axis) activity versus inhibitor units (x axis). When defining a patient’s inhibitor titer, derive the inhibitor titer from the graph and multiply by the dilution to obtain the final titer.

**Types of inhibitors**

| Kinetics | Clinical syndrome |
|----------|------------------|
| Type I   | Alloantibodies arising in a person with congenital haemophilia treated with FVIII concentrates |
| Type II  | Autoantibodies as seen in acquired haemophilia A |

**Autoimmune FVIII inhibitors cause acquired hemophilia A.** Alloimmune FVIII inhibitors occur in patients with congenital hemophilia A and render the replaced FVIII less or not effective. These are the most common specific factor inhibitors.***
Do not order baseline coagulation tests for asymptomatic patients having low-risk non-cardiac surgery.

Canadian Anesthesiologists’ Society, Choosing Wisely Canada recommendation #1.

In a study evaluating subjects referred to hematologists for bleeding disorder assessment, PT and PTT had a sensitivity of 1.0-2.1% for ruling out bleeding disorders[9]. Therefore, a normal PT and PTT does not rule out the presence of a bleeding disorder.

In a retrospective study of ~1 million preoperative patients [4], 94% of testing was unnecessary. 26% of patients had preoperative PT testing.

23% of patients had preoperative aPTT testing. 99.9% of this testing was unnecessary.

The majority of preoperative PT and PTT tests are unnecessary.

**When to order coagulation tests (PT/INR and aPTT) in a preoperative patient**

**Consider PT/INR**
- Vitamin K antagonist (warfarin)
- Liver disease
- Patients at risk for Vitamin K deficiency (e.g. malnutrition, fat soluble vitamins, cholestasis, prolonged antibiotics)

**Consider aPTT**
- Planned intraoperative IV heparin (e.g. cardiac or vascular surgery)
- Suspected hemophilia A/B, factor XI deficiency, severe von Willebrand disease
- Suspected antiphospholipid syndrome

**Top five reasons NOT to order PT/INR or aPTT**

1. Routine blood work
2. Routine pre-op screen in a low risk non-cardiovascular surgery patient
3. Monitoring of direct oral anticoagulants (DOAC)
4. Monitoring of low molecular weight heparin (LMWH)
5. Monitoring of thromboprophylaxis
Effect of Direct Oral Anticoagulants on Hemostatic Tests

| Below on-therapy range | On therapy range | Above on-therapy range |
|------------------------|------------------|------------------------|
| **Dabigatran**         |                  |                        |
| TT                     | Dilute TT, ECT, ECA | aPTT                  |
| aPTT                   | PT               |                        |

| **Rivaroxaban**        |                  |                        |
| Anti-Xa activity       | PT               | aPTT                  |

| **Apixaban**           |                  |                        |
| Anti-Xa activity       | PT               | aPTT                  |

| **Edoxaban**           |                  |                        |
| Anti-Xa activity       | PT               | aPTT                  |

Horizontal bars correspond to the approximate range of detectability (sensitivity) and checkered area corresponds to linearity of each assay at below, within and above typical on therapy concentrations of dabigatran, rivaroxaban, apixaban and edoxaban. Ranges are approximations and may vary depending on the choice of reagent.

ECA = ecarin chromogenic assay; ECT = ecarin clotting time; TT = thrombin time

Adapted from Cuker et al. with permission[5,15]
ILLUSTRATED REVIEW

RELATIONSHIP DISCLOSURE
The authors declare no conflicts of interest.

AUTHOR CONTRIBUTIONS
CE and MS developed the concepts and images, wrote the manuscript, and approved the final content.

TWITTER
Carolyne Elbaz @ElbCarolyne
Michelle Sholzberg @sholzberg

REFERENCES
1. Bakhtiari K, Meijers JCM, De Jonge E, Levi M. Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation. Crit Care Med. 2004;32(12):2416–21.
2. Bowman M, Mundell G, Grabell J, Hopman WM, Rapson D, Lillicrap D, et al. Generation and validation of the Condensed MCMMDM-1VWD Bleeding Questionnaire for von Willebrand disease. J Thromb Haemost. 2008;6(12):2062–6.
3. Bowman M, Riddel J, Rand ML, Tosetto A, Silva M, James PD. Evaluation of the diagnostic utility for von Willebrand disease of a pediatric bleeding questionnaire. J Thromb Haemost. 2009;7(8):1418–21.
4. Capoor M, Stonemetz J, Baird J, Ahmed F, Awan A, Birkenmaier C, et al. Prothrombin time and activated partial thromboplastin time testing: a comparative effectiveness study in a million-patient sample. PLoS ONE. 2015;10(8):e0133317.
5. Cuker A, Husseinzadeh H. Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review. J Thromb Thrombolysis. 2015;39(3):288–94.
6. Deforest M, Grabell J, Albert S, Young J, Tuttle A, Hopman WM, et al. Generation and optimization of the self-administered bleeding assessment tool and its validation as a screening test for von Willebrand disease. Haemophilia. 2015;21(5):e384–8.
7. Elbatarny M, Mollah S, Grabell J, Bae S, Deforest M, Tuttle A, et al. Normal range of bleeding scores for the ISTH-BAT: adult and pediatric data from the merging project. Haemophilia. 2014;20(6):831–5.
8. Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome. N Engl J Med. 2018;378(21):2010–21.
9. Haywood CM, Moffat K, Liu Y. Laboratory investigations for bleeding disorders. Semin Thromb Hemost. 2012;38(7):742–52.
10. Kitchens CS. Prolonged activated partial thromboplastin time of unknown etiology: a prospective study of 100 consecutive cases referred for consultation. Am J Hematol. 1988;27:38–45.
11. Poller L. International Normalized Ratios (INR): the first 20 years. J Thromb Haemost. 2004;2(6):849–60.
12. Quick AJ. The clotting time - an enigma resolved. Am J Clin Pathol. 1974;62(5):670–2.
13. Rodeghiero F, Castaman G, Tosetto A, Batlle J, Baudo F, Cappelletti A, et al. The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: An international, multicenter study. J Thromb Haemost. 2005;3(12):2619–26.
14. Rodeghiero F, Tosetto A, Abshire T, Arnold DM, Coller B, James P, et al. ISTH/SSC bleeding assessment tool: A standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost. 2010;8(9):2063–5.
15. Samuelson BT, Cuker A, Siegal DM, Crowther M, Garcia DA. Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review. Chest. 2017;151(1):127–38. https://doi.org/10.1016/j.chest.2016.08.1462.
16. Spradbrow J, Letourneau S, Grabell J, Liang Y, Riddel J, Hopman W, et al. Bleeding assessment tools to predict von Willebrand disease: Utility of individual bleeding symptoms. Res Pract Thromb Haemost. 2020;4(1):92–9.
17. Tosetto A, Rodeghiero F, Castaman G, Goodeve A, Federici AB, Batlle J, et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMMDM-1 VWD). J Thromb Haemost. 2006;4(4):766–73.
18. Local data obtained from St. Michael’s Hospital Laboratory Information System.

How to cite this article: Elbaz C, Sholzberg M. An illustrated review of bleeding assessment tools and common coagulation tests. Res Pract Thromb Haemost. 2020;4:761–773. https://doi.org/10.1002/rth2.12339